Table 2.
Pathogenetic characteristics of 461 cases of de novo DLBCL treated with R-CHOP immunochemotherapy
| Overall | CD30+ | CD30– | P value | |
|---|---|---|---|---|
| COO classification | ||||
| GCB | 235 (51%) | 38 (59%) | 197 (50%) | .1640 |
| ABC | 223 (49%) | 26 (41%) | 197 (50%) | |
| BCL2 expression | 228/454 (50%) | 26/65 (40%) | 202/389 (52%) | .0750 |
| BCL6 expression | 369/449 (82%) | 51/62 (82%) | 318/387 (82%) | .9867 |
| MYC expression | 295/455 (65%) | 38/64 (59%) | 257/391 (66%) | .3237 |
| MYC/BCL2 coexpression | 155/452 (34%) | 15/64 (23%) | 140/388 (36%) | .0483 |
| MYC/BCL6 coexpression | 249/445 (56%) | 33/64 (52%) | 216/381 (57%) | .4443 |
| BCL2 aberration | 129/395 (33%) | 14/59 (24%) | 115/336 (34%) | .1128 |
| MYC aberration | 33/303 (11%) | 0/46 (0%) | 33/257 (13%) | .0100 |
| BCL6 aberration | 202/294 (69%) | 24/42 (57%) | 178/252 (71%) | .0808 |
| TP53 mutation | 107/461 (23%) | 11/65 (17%) | 96/396 (24%) | .1952 |
| P53 expression | 163/449 (36%) | 28/62 (45%) | 135/387 (35%) | .1182 |
| P21 expression | 57/449 (13%) | 15/62 (24%) | 42/387 (11%) | .0034 |
| Ki-67 | 303/454 (67%) | 36/64 (56%) | 267/390 (68%) | .0546 |
*
Cutoff for each of the biomarkers is detailed in the “Materials and methods” section.